Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Key Sessions

Philipp Gasparon

KEYNOTE: Feedback from the EU Commission on competition law

European Commission

08:00 09:00 (60 mins)

Main agenda


08:50 09:00 (10 mins)

Main agenda

Opening remarks from the morning chairperson

  • Mélanie Thill-Tayara - Antitrust/Competition Partner , Dechert LLP

09:00 09:40 (40 mins)

Main agenda

KEYNOTE: Feedback from the EU Commission on competition law

  • Recent developments in the pharmaceutical industry on excessive pricing
  • Reverse payment settlements
  • Lifecycle management strategies
  • Philipp Gasparon - Acting Head of Unit, Pharma Antitrust Unit, DG Competition, European Commission

09:40 10:40 (60 mins)

Main agenda

Interactive discussion forum: Reverse payment patent settlements – lessons learnt from the Lundbeck case

  • What are the key points of the case?
  • What are the lessons learnt for originator and generics companies?
  • Matthieu Guérineau - Contract Department Director, Les Laboratoires Servier
  • Brian Sher - Partner, CMS

10:40 11:20 (40 mins)

Main agenda

Morning networking refreshments

11:20 12:00 (40 mins)

Main agenda

Dual dialogue: Excessive pricing, discounts and rebates in the EU

  • Abusive dominance through excessive pricing: what is the current status in the pharmaceutical industry?
  • Examining the expanding nature of abusive cases
  • Examining decisions on pricing and rebates
  • David Hull - Partner, Van Bael & Bellis
  • Bernardine Adkins - Partner, Gowling WLG

12:00 13:00 (60 mins)

Main agenda

Panel discussion: Recent EU merger control cases in the pharmaceutical industry

  • Review of high profile cases
  • Assessing the key issues and pitfalls
  • Future developments


  • Alberto Bacchiega - Head of Unit - Merger control, DG Competition , European Commission
  • Tony Woodgate - Partner, Simmons & Simmons
  • Stephen Mavroghenis - Global Head Antitrust Group, Shearman & Sterling

12:40 14:10 (90 mins)

Main agenda

Networking lunch

14:10 14:50 (40 mins)

Main agenda

Dual dialogue: Second Medical Use Patents

  • Understanding the enforcement and validity of second medical use patents
  • Ensuring reasonable protection for second medical use patents
  • Ensuring the patent is respected whilst allowing free competition for the generics
  • Enforcement against skinny/cross-label uses 
  • Impact of national regulatory practice on patent infringement
  • Examining the latest case law (Lyrica, Pfizer and Actavis)
  • Kai Rüting - Partner, VOSSIUS & PARTNER
  • Dr Jennifer Antcliff - Senior Associate, Carpmaels & Ransford

14:50 15:30 (40 mins)

Main agenda

Dual dialogue: Assessing the current status of SPCs: shortcomings of the regulation, current case law and the impact of the political landscape

  • Examining the current shortcomings of the SPC regulation – unforeseen consequences, regular referrals to the Court of Justice, non-standard product type and a lack of clarity
  • Highlighting the current case law on SPC regulations
  • Understanding the impact of Brexit on SPC regulations
  • What does an SPC mean for new molecules and biologics?
  • Brian Cordery - Partner, Bristows LLP
  • Jürgen Dressel - Head Global Patent Litigation Strategy, Novartis Pharma

15:40 16:10 (30 mins)

Main agenda

Afternoon networking refreshments

16:10 16:40 (30 mins)

Main agenda

Dual Dialogue: An update on the Unified Patent Court – structure, current status and impact on industry

  • What is the current structure of the UPC?
  • Assessing the implications of Brexit on the UPC – how might it affect collaborations with other parties?
  • What does Brexit mean for the protection of IP?
  • Marianne Schaffner - Partner, Dechert
  • Alan Johnson - Partner, Bristows

16:40 17:10 (30 mins)

Main agenda

Cross border relief and patent infringement – examining the latest case law

  • Assessing the current state of play
  • Lessons for industry
  • Galit Gonen - SVP, General Counsel & IP, Teva Europe

17:10 17:20 (10 mins)

Main agenda

Chair's closing remarks and end of competition day